X4 Pharmaceuticals Issues Stock Options to Executives After $85 Million Funding
Table of Contents
BOSTON, August 16, 2025 – X4 Pharmaceuticals (Nasdaq: XFOR), a biopharmaceutical company focused on rare immunological diseases, announced inducement awards to three newly appointed executive officers on August 12 and August 14, 2025. The awards consist of stock options designed to align executive interests with company performance and growth.
Executive Inducement Awards
The company issued options to purchase a combined 13,865,331 shares of X4’s common stock to Adam Craig, M.D., John Volpone, and david Kirske. These grants were made under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan and approved by the company’s Board of Directors. The additional awards issued on August 14 were specifically intended to adjust ownership percentages following a recent $85 million private placement.
Dr. Craig received options for 4,779,919 shares, Mr. Volpone for 4,779,919 shares, and Mr. Kirske for 3,186,193 shares.
Did You Know?
Inducement awards are commonly used to attract and retain key talent, notably in the biotechnology sector where equity compensation is prevalent.
Option Details
Options granted on August 12, 2025, have a ten-year term and an exercise price of $1.42 per share, matching the closing price of X4’s stock on August 11, 2025. Options issued on August 14, 2025, also have a ten-year term, with an exercise price of $3.14 per share, aligning with the closing price on August 14, 2025.
| Executive | options (Aug 12) | Options (Aug 14) | Total Options |
|---|---|---|---|
| Adam Craig, M.D. | 4,250,718 | 529,201 | 4,779,919 |
| John Volpone | 4,250,718 | 529,201 | 4,779,919 |
| David Kirske | 2,833,812 | 352,800 | 3,186,612 |
Vesting schedules vary by executive. dr. Craig and Mr. Volpone’s options vest over three years, with one-third vesting after 12 months and the remainder monthly over the following 24 months, contingent on performance and continued employment. Mr. Kirske’s options have both 18-month and three-year vesting schedules, also subject to performance and employment conditions.
About X4 Pharmaceuticals
X4 Pharmaceuticals is dedicated to developing and commercializing therapies for rare diseases of the immune system. The company’s lead product, mavorixafor, an orally available CXCR4 antagonist, is marketed in the U.S. as XOLREMDI®. X4 is also conducting a Phase 3 clinical trial, 4WARD, evaluating mavorixafor for chronic neutropenic disorders.
pro Tip:
CXCR4 antagonists work by blocking the CXCR4 receptor, which plays a role in immune cell trafficking and activation.
The company is headquartered in Boston, Massachusetts. For more information, visit www.x4pharma.com.
Investor Contact
Candice Masse
astr partners
[email protected]
(978) 879-7273
What impact will these inducement awards have on X4 Pharmaceuticals’ long-term growth strategy? How will the 4WARD clinical trial influence the company’s future direction?
The biopharmaceutical industry is experiencing rapid innovation, particularly in the area of rare disease treatments. Companies like X4 Pharmaceuticals are at the forefront of this progress, leveraging advancements in immunology and drug growth to address unmet medical needs. The use of stock options as an inducement for key personnel is a common practice, reflecting the competitive landscape for talent in this sector. The success of mavorixafor and the outcome of the 4WARD trial will be critical factors in determining X4’s future trajectory.
Frequently Asked Questions about X4 pharmaceuticals
- What is X4 Pharmaceuticals’ primary focus? X4 Pharmaceuticals focuses on developing and commercializing therapies for rare diseases of the immune system.
- What is mavorixafor? Mavorixafor is an orally available CXCR4 antagonist marketed as XOLREMDI® in the U.S.
- What is the 4WARD clinical trial? The 4WARD trial is a Phase 3 clinical trial evaluating mavorixafor for chronic neutropenic disorders.
- What are inducement awards? Inducement awards are stock options granted to new executive officers to attract and retain talent.
- Where is X4 Pharmaceuticals headquartered? X4 Pharmaceuticals is headquartered in Boston, Massachusetts.
We hope this article provided valuable insight into X4 pharmaceuticals’ recent executive compensation decisions. Share this article with your network and join the conversation in the comments below!
